6

Vaccine Administration protocols (best practices) Safety Precautions, and Immunoprophylaxis

AUTHORS DETAIL

Faryal Ikram1, Areej Tanveer1*, Wania Rehman1, Areeba Adeem1, Razia Arif Butt1, Bisma Razzaq1, Shiza Iqbal1, Amina Ghani1, Alveena Gull1, Mahnoor Khan1

1 Department of Pathobiology and Biomedical Sciences, Muhammad Nawaz Shareef University of Agriculture, Multan, 60000, Pakistan.

*Corresponding author: areejtnveer@gmail.com

Received: 27-Nov-2024 **Revised:** 19-Dec-2024 **Accepted:** 29-Dec-2024

Cite this Article as: Ikram F, Tanveer A, Rehman W, Adeem A, Butt RA, Razzaq B, Iqbal S, Ghani A, Gull A and Khan M, 2024. Vaccine Administration protocols (best practices) Safety Precautions, and Immunoprophylaxis. In: Ahmad B, Ali Z, Dayong S and Aziz M (eds), Anim Health Dis Management, Pioneer Page Publishers, Beijing, China, Vol. 1: 34-43.

Abstract

Vaccination, a critical public health intervention, has historically been proven to prevent infectious diseases and enhance community health. The evolution of vaccines has led to significant advancements in disease prevention, improving public health outcomes, and developing multiple vaccine technologies. Best practices in vaccine administration include thorough risk analysis, screening of the patient, and adherence to the Immunization Guide, which emphasizes the importance of healthcare personnel training and immunization pain management strategies. Proper needle selection and injection site considerations are vital to ensure potency and minimize adverse reactions. Safety precautions, including infection control measures and effective handling of vaccines, are essential to maintain vaccine integrity. Because of the diverse nature and unique characteristics of vaccines, individual vaccine examination is pivotal during vaccine administration. Different types of vaccines, such as live attenuated, inactivated, conjugate, and combination vaccines, require tailored approaches to ensure efficacy and safety considerations. Therefore, understanding immunoprophylaxis and the concept of herd immunity is crucial for community health protection. Despite these protocols, global challenges like misinformation and access imbalance threaten vaccination efforts.

Keywords: Vaccine intervention, Protocols, Safety and security measures, Healthcare measures, Vaccine integrity, Immunoprophylaxis.

1. Introduction

A vaccine is a biologically prepared product that provides prevention against particular diseases by inducing immunity. (Kavanaugh et al., 2023). Many infections related to childhood are avoided and millions of lives are secured from infectious diseases by vaccination. About 10 million lives were saved with viral vaccines of measles, chickenpox, mumps, rubella, and hepatitis A, being manufactured from cell culture substratum from the 1960s to 2015 (Orenstein and Ahmed, 2017; Olshansky and Hayflick, 2017).

Edward Jenner used the terminology of vaccine for the first time in the 18th century by vaccinating a boy in 1796 with cowpox abrasions from the hand of milkmaids, thus, eventually providing immunity against smallpox. In 2019, the first Ebola virus vaccine was approved by the European Medical Agency (EMA) and by the Food and Drug Administration (FDA) which was found to be approximately 95-100% productive against the Ebola virus (Tomori & Kolawole, 2021). In 2020, the trials for producing a secure and effective vaccine were started for COVID-19, and on 31st December 2020, the World Health Organization provided an emergency list for the mRNA vaccine (Pfizer vaccine). Consequently, this shows that vaccines are important to prevent mortality and morbidity by helping the immune system to make antibodies against that particular disease. The vaccine uses the body's natural defence mechanism to make the immune system stronger and build resistance against specific injections (Wallis et al., 2019).

2. Protocols in vaccine administration

2.1. Risk Analysis and Assessment of risk-benefit Before Vaccination

A careful approach is necessary to completely examine risk before vaccine administration. Epidemiological data is important to understand the disease epidemiology for accessing the effectiveness of vaccines which can either be direct in which there is the reduction of disease incidence or indirect i.e., immunity to herd effects (Hanslik & Boëlle, 2007). On the other hand, quantitative risk-benefit models are applied that help the decision-makers to examine the benefits and risks during the vaccine's lifecycle (Arlegui et al., 2020).

2.2. Safety monitoring by risk management and identification

The post-marketing monitoring is essential for determining the unpredictable harmful effects compelling the strong vaccine vigilance systems (Hanslik & Boëlle, 2007). To evaluate vaccine administration, advanced epidemiological and statistical methods are used throughout the lifecycle of the Food and Drug Administration handling approaches (Ball et al., 2011). The possible risks throughout the vaccine development are monitored which include biological hazards and technical errors (Pasquale et al., 2016). So, for proper monitoring, educating healthcare providers and the public about the benefits and risks, clear communication strategies are essential (Hanslik & Boëlle, 2007).

2.3. Preparation for Vaccination (Patient screening, consent)

2.3.1. Patient Screening: The process for screening the patient and the parents must be short and addressed according to the particular needs. To recognize any adverse reaction or allergies that can affect vaccine administration, a thorough health assessment is essential before vaccination. (Marrero and Suarez, 2021). Specific guidelines according to age are given which requires special attention, especially in children.

2.3.2. Informed Consent: Providing assessable and complete information about the vaccine's procedure, benefits, and risks is the basis of informed consent. It ensures that decisions are made independently and without any pressure. Parental consent is almost always required for minors, however, some administrations allow for youngsters ' consent, which increases the vaccination uptake (Fisher et al., 2018).

3. Training and competency of healthcare personnel

The educational perspective on training and competence is reviewed by educated and expert people and built into the developmental process. Cross-cutting competency relates to an intended audience within the department of healthcare personnel in which they are not restricted to nurses or physicians. The advisory group evaluates two types of competency forms like competency evaluation form and the terminal objectives form, containing a questionnaire, and the response is in an agree-to-disagree form (Arede et al., 2019).

4. Immunization pain management strategies

The pain caused by vaccine injection results in hesitation in vaccine administration throughout life (Taddio et al., 2009; Taddio et al., 2012). People with a fear of needles due to bad experiences with vaccination show adverse behavior (McMurtry et al., 2015). Suggesting anesthetics before vaccine injections for children at the age of 12 or under 12, for example; local anesthetics include creams, gels, and patches, resulting in the reduction of pain signals from the skin (McLure and Rubin, 2005).
Therefore, for good vaccination in clinical practice, reduction of pain is considered very important by the World Health Organization. It is considered the most useful therapy from the guideline for worldwide implementation. Procedures such as oral lectures, films, and best practices for healthcare workers are good for educating the people about reduction of pain (Taddio et al, 2015).

5. Needle (size and type) selection based on patient characteristics

Needles used beneath the skin are obtainable in a broad range of sizes for delivering drugs, and vaccines, into the body or for removing fluids and tissue samples. The suitable needle measuring device varies and it depends on some factors like target tissue and injection formulation. Such as phlebotomy needs the use of syringes of about 22- 21 gauge inserted to the deepest of about 25-38 mm to extract blood in millimeters (Kim et al., 2017; Hoffman et al., 2023). But the vaccine usually uses a

syringe of less than 1 ml of fluid and 25 – 22-gauge syringes with a diameter of 16- 38 millimeters are enough (Kroger et al., 2006).

6. Routes of vaccine administration

Intramuscular injection has great supply, so pain is greater as compared to subcutaneous injection (Haas et al., 2019). But, in some cases like the Anthrax vaccine (Marano et al., 2003) subcutaneous injection pain is increased same as in MMR45 and DT toxoid vaccine (Lafeber et al., 2001; Riedmann 2014). The specific intramuscular direction was at a higher level than the oral direction in the salmonella vaccine as better prior protection in young calves (Makoschey, 2015).

7. Infection control measures

One of the strategies that we used to prevent or control the infection is to use needles and syringes that are properly disinfected and for a single injection, each unit of renewed medication should be used. Improper sterilization techniques may become the cause of infection (Hauri et al., 2003).

7.1. Hand hygiene and the use of gloves during administration

Before preparing the injection material washing and sanitizing of hands are very necessary to prevent infection. Proper hand sanitization (with an alcohol-based waterless antiseptic) impacts health in good manners for all age groups which includes children as well as childcare providers.

7.2. Patient immunization background

Examination of the developed immunization programs is done, based on the patient experience already reported in the past. The majority of the individuals were reimmunized successfully with the help of AEFI (adverse events following immunization) (Ko et al., 1995; Gold et al., 2000; Baxter et al 2010; Micheletti et al., 2011). Approximately twenty-eight percent of general neonatologists participated in a poll conducted in 2013, Canada, found that they had difficulty or risk factors AEFI to vaccination, which may make them worry about receiving vaccination in future (Top et al., 2014).

8. Access for allergic reactions and anaphylaxis management

A systematic study about anaphylaxis management and enhancing therapies for anaphylaxis showed the use of H1 and H2 antihistamines. Both drugs are effective in combined form because H1 and H2 blockade are more effective than H1 alone (Choo and Sheik, 2007; Nurmatov et al., 2008).

8.1. Reactions in hypersensitive and immunocompromised patients

Adverse vaccine reactions are increasing due to improper vaccine administration and lack of protocol follow-up, such reactions consist of rare yet fatal immune-reactive reactions causing harm to the patients (Chung, 2014). About 180 participants were mentioned for adverse reactions upcoming COVID-19 vaccination along with hypersensitive symptoms and reactions in a study demonstrating the analysis of participants designated for pre-vaccination assessment (Fitzpatrick et al., 2024). Thus, showing the significance of proper and authentic specialist evaluation and monitoring facilitates safe vaccine administration.

9. Safety precaution

9.1. Handling of vaccines

Keeping vaccines safe refers to following strict cold storage rules and safely mixing vaccines with the right handling methods (Objio, 2019).

9.1.1. Cold chain management and regulatory infrastructure: Vaccines must be stored and carried at specified temperatures to maintain their effectiveness otherwise, deviations can result in the loss of medicinal qualities (Pogarskaya and Konfino, 2022). The ideal temperature is between 2°C and 8°C. Some mRNA requires highly cold conditions like -70°C or below. Any difference can make them ineffective as well as reduce their potency (Kartoglu and Ames, 2022). Cold chain management requires strong infrastructure, temperature monitoring, and qualified workers to follow storage requirements (Thakur, 2021; Fahrni et al., 2022), and regulatory compliance ensures cold chain integrity across logistics (Fahrni et al., 2022). For instance, the logistics of last-mile Cold-chain operations for COVID-19 vaccines indeed pose numerous or complex sets of challenges i.e., low -temperature storage and transportation.

9.1.2. Proper Handling Techniques: Vaccines should be stored in designated refrigerators or freezers, with regular checks to ensure optimal conditions and maintenance of efficacy could be made possible by reducing the number of times vaccines are removed from storage. Similarly, proper techniques for reconstitution should be adopted such as using sterile diluents and manufacturer instructions to ensure safety and effectiveness (Armstrong, 2018).

9.2. Adverse event reporting and management

Adverse events (AEs) refer to any unwanted reactions to medicine at clinical levels, barring failures or accidental overdoses which include allergic reactions, skin rashes, and systemic symptoms that can occur in 1- 15% of medication administrations (Bhowmik et al., 2013).

9.2.1. Reporting and management of AEs: Healthcare personnel must report adverse events (AEs) to pharmacovigilance systems to ensure drug safety and efficacy (Fischer et al., 2015). Adverse drug reactions (ADRs) are a primary cause of hospitalization; thus, it's crucial to report any new side effects that may not have been detected during clinical studies (Bhowmik et al, 2013). For management purposes:

- Topical corticosteroids or antihistamines are commonly used to treat redness and reduce inflammation and pain.
- For pain, analgesics are generally prescribed that may be discontinued as per need.
- Ice packs and elevation can alleviate swelling, whereas systemic corticosteroids may be necessary for severe cases (Krantz et al., 2021).

10. Vaccine schedule

Vaccination schedules usually consist of three to four doses spaced out across four to six months, while some immunizations ask for a booster shot throughout one's lifetime. Multi-dose series are given to stimulate an individual's desired immunological response to a sufficient degree of protection and to raise the proportion of the vaccinated population that is no longer susceptible and produce a "herd effect" (Scarabaggio et al., 2021).

Significant advancements i.e., meta-analyses, and post-marketing epidemiology studies compare various schedules side by side, producing crucial evidence that some vaccines can remain protective after fewer doses, and some regulatory management authorities have updated their suggested vaccine schedules accordingly (Lofano et al., 2020).



Fig. 1: Herd immunity: Demonstrating the facts for a pathogenic (disease) spread in a population

10.1. Herd Immunity (Community or Population immunity)

Herd immunity relates to the fact that not everyone in a population needs to be immune to stop the spread of disease. If 95% of the people in a population are immune, either from vaccination or getting recovered from the disease, creating a protective barrier. This makes it harder for the disease to spread widely, even to those who are not immune. Fig. 1 illustrates herd immunity, a sample of a population from primary infection becomes immune, causing protection of the rest of the population from that specific pathogen (Smith, 2019; Duffy and Duffy, 2023). In addition to encouraging prosocial vaccination to protect others, herd immunity can also encourage free riding, in which people benefit from the protection that a well-vaccinated society offers without making any contributions to herd immunity (Fine et al., 2011).

11. MECHANISMS OF IMMUNE PROTECTION

11.1. Initiation of Mucosal Immune Response

Mucosal antibodies are very important for the protection of upper airways which are the main site for entry of viruses. Mucosal antibodies are potentially associated with the prevention of influenza and help in the initiation of mucosal immunity thus producing secretory IgA, with the mucosal IgA response that is associated with hemagglutination inhibition titer (Ambrose et al., 2012; Wright et al., 2016; Mohn et al., 2016). This mucosal response may remain for up to 6 months (Mohn et al., 2016) and is associated with prevention from upcoming shedding of LAIV or some infection of viruses (Belshe et al., 2000; Ambrose et al., 2012).

11.2. Induction of Innate Immunity

As LAIV simulates a natural influenza infection, this immunization exhibits a capacity to develop innate immune pattern recognition receptors, including Toll-like receptors, thereby facilitating the secretion of type I interferons (IFNs), chemokines, and pro-inflammatory cytokines. This mechanism leads to the recruitment of immune cells to the respiratory airways, the guidance of the evolving adaptive immune response, and the maturation of dendritic cells (Iwasaki and Pillai 2014; Pulendran and Maddie 2015). Considering the crucial role of many cytokines and interferon in the maturation of antigen-presenting cells (APCs) for the priming of adaptive immune response (Pulendran and Maddur 2015), the capacity of LAIV to elicit innate immunity is presumably a fundamental element essential for the development of the cellular immune response induced by LAIV.

12. Immunoprophylaxis

Since immunity functions through previous exposure to pathogens, triggering a person's immune response can act as a preventive measure. Prophylaxis is a preventive medical strategy applied before a disease develops, while treatment methods are used to handle an existing illness (Duffy and Duffy, 2023).

12.1. Types of Immunoprophylaxis

12.1.1. Active prophylaxis (Vaccine): A person who has been vaccinated is referred to as a vaccinated individual. Active immunization involves introducing a prepared virus to trigger the body's immune system to generate its own targeted immunity. Currently, available viral vaccines include (1). Attenuated live viruses; (2) inactivated viruses; and (3) antigens produced through recombinant technology (Goldenthal et al., 2011).

12.1.2. Immune Response to Vaccines: Vaccination prompts the production of antibodies and activates T lymphocytes. Vaccine efficacy is measured by the proportion of individuals protected and the strength and duration of immunity conferred. The most effective viral vaccines protected over 90 percent of individuals and provided relatively long-lasting immunity (Delany et al., 2014).

12.1.3. Passive prophylaxis: Passive immunity is provided by administering antibodies produced in another individual or host. Human immunoglobulins continue to play a crucial role in passive prophylaxis (and occasionally in treatment) for viral diseases (Lachmann, 2012). They are commonly used to safeguard people who have been exposed to a disease and cannot be protected through vaccination.

12.2. Advanced Techniques

From a recovered individual, B cells are collected, and potent neutralizing antibodies are isolated to obtain the corresponding antibody genes, which are then cloned and sequenced as given in Fig. 2 (Campbell et al., 2023). The gene sequences for the variable regions of the heavy and light antibody chains are inserted into an Adeno-associated virus (AAV) vector. These engineered AAV vectors, designed to produce the desired monoclonal antibodies (m Abs), are produced and delivered into muscle tissue via injection. The modified muscle cells subsequently release these mAbs into the bloodstream, allowing them

to circulate through the body and provide long-lasting, comprehensive defense against the intended pathogen (Campbell et al., 2023).



Fig. 2: Generation of a defense mechanism by producing antibodies through Adeno-associated virus vectors (AAV vectors) administration

13. Case studies and upcoming challenges

13.1. Case studies

13.1.1. Fractional dose of inactivated poliovirus vaccine (Intradermal delivery)

A part of the Global Polio Eradication Initiative's (GPEI) strategy, inactivated poliovirus vaccine (IPV) is endorsed in all immunization programs in coincidence with three doses of bivalent oral poliovirus vaccine (BOPV) (Sutter et al., 2024). In the identification of finite supply and high costs of IPV, two fractional doses were approved for routine immunization and one fractional dose for campaigns (with BOPV) (Mashunye, 2019).

13.1.2. Microarray patches for Measles-Rubella vaccine delivery

In composing for future global eradication, the task of the global Measles & Rubella Initiative is to attain measles and rubella eradication by 2020 in five WHO regions. Before injection, the Measles-Rubella vaccine is freeze-dried and restored with a supplied diluent, in a cold chain (WHO, 2006). It results in reconstitution errors with the use of incorrect diluent, which leads to disadvantages including immunizations and death. Eventually, such practices may diminish vaccine wastage, but they also lead to a decrease in vaccine coverage (Lazarus et al., 2022).

13.2. Challenges in reaching underserved populations

During vaccine administration (of COVID-19 clinical trials), ethnic minorities have been compatibility considered underrepresented, even though they seem to be unequally affected by the disease (Etti et al., 2021). People with no homes bear higher mortality rates as compared to the general population, largely set down to infectious diseases, mental health issues, drug and alcohol abuse etc. (Ojo-Fati et al., 2017). Distrust and rumors about vaccines affect the population and could arise due to misguidance thus, propelling vaccine boycotts, and ceasing immunization programs (Renne, 2006; Mrozek-Budzyn et al., 2010; Nasiru et al., 2012).

13.2.1. Role of International Organizations (WHO, GAVI, FDA) in promoting Vaccine: Major donors and creditors i.e., the World Bank and other external developmental banks, have labeled billions of dollars in funds for COVID-19 vaccination programs in poor-income countries (Duggan et al., 2020; Senasi, 2020; Chakraborty et al., 2021). These funds can be used to purchase vaccines that have been permitted by firm regulatory bodies or WHO. To prevent any repeat of the H1N1

scenario, the COVID-19 vaccine global access (COVAX) facility, in partnership with GAVI and CEPI, was created in coordination with WHO. The optics of this advocate towards a partial focus on vaccines under GAVI can be seen in the contrast when GAVI was founded vs Non-GAVI DAH where various resources have been separated into respective specific allocations for vaccines, research, system broadening and kind of development (Ikilezi et al., 2018). Depending on the importance, the FDA may permit an EUA, which allows for the fast development of an unauthorized vaccine following promptly providing individual and community protection (Desai et al., 2024).

14. Maintaining vaccine integrity in low resource setting

For faster vaccine development, utilizing mRNA platforms as seen during the COVID-19 pandemic, and supporting local manufacturing capabilities helps to ensure the supply of vaccines and reducing dependence on global supply chains. An efficient regulatory process for vaccine approval can facilitate quicker access to vaccines, especially in emergencies (Borah, 2020). Using silica to stabilize vaccine proteins is a promising approach, especially for improving vaccine storage and distribution in regions with limited cold chain infrastructure (Kumar et al., 2022).

15. Vaccines Misinformation and Ensuring Public Trust

Trust in vaccines and the health system is crucial for effective public health programs, particularly for those delivering life-saving vaccines. In vaccine development and distribution, the “Vaccine confidence gap”, is attributed to an increasingly complex immunization schedule and the fast spread of information and misinformation about vaccines. Community engagement has been the focus of collaboration with stakeholders such as parents, health professionals, community leaders, and policy-makers, as well as Organizations such as the Red Cross, UNICEF, and WHO to combat misinformation and provide essential information and health services (Sommariva et al.,2021). They emphasize the importance of understanding the different elements of Society, Culture and Politics (Erchick et al., 2022).
Anti-vaccine movements continue to impact public attitudes toward vaccines and mandate-vaccine narratives significantly increase vaccine hesitancy, especially among those who are uncertain about vaccines. This hesitancy often leads individuals to seek exemptions, delay vaccinations, or refuse vaccination for themselves or their children. COVID-19 vaccinations become non-mandatory in various regions and fostering public trust and understanding is crucial for their success (Pagliaro et al., 2021).

Conclusion

Vaccines, a biomedical legacy, when administrated inside the body of an organism induce immunity. For authentic and accurate vaccine administration, the rule of thumb is to follow all the rules and regulations provided by the organizations, and certain practices can also be adopted to enhance the productiveness of the vaccine. Future predictions and precautions in vaccination and immunoprophylaxis technologies include the legitimate use of a particular vaccine and its reliable cold storage for managing any sort of adverse and hypersensitivity reactions in patients.

References

1. Ambrose, C. S., Wu, X., Jones, T., & Mallory, R. M. (2012). The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. Vaccine, 30(48), 6794-6801.
2. Arede, M., Bravo-Araya, M., Bouchard, É., Singh Gill, G., Plajer, V., Shehraj, A., & Adam Shuaib, Y. (2019). Combating vaccine hesitancy: teaching the next generation to navigate through the post truth era. Frontiers in public health, 6, 381.
3. Arlegui, H., Bollaerts, K., Salvo, F., Bauchau, V., Nachbaur, G., Bégaud, B., & Praet, N. (2020). Benefit–Risk Assessment of Vaccines. Part I: a systematic review to identify and describe studies about quantitative benefit-risk models applied to vaccines. Drug Safety, 43, 1089-1104.
4. Armstrong, K. (2018). The safe storage and management of vaccines. Practice Nursing, 29(4), 167-170.
5. Ball, R., Horne, D., Izurieta, H., Sutherland, A., Walderhaug, M., & Hsu, H. (2011). Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration. Pediatrics, 127(Supplement_1), S31-S38.
6. Baxter, D. N., Ghebrehewet, S., & Falconer, M. (2010). Referrals to a pediatric immunization service: findings from a practice-based audit of a UK specialist immunization clinic. Human Vaccines, 6(5), 420-424.

7. Belshe, R. B., Gruber, W. C., Mendelman, P. M., Mehta, H. B., Mahmood, K., Reisinger, K., … & Wolff, M. (2000). Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. The Journal of infectious diseases, 181(3), 1133-1137.
8. Bhowmik, D., Gopinath, H., Kumar, B. P., Duraivel, S., & Kumar, K. S. (2013). Nutraceutical-a bright scope and opportunity of Indian healthcare market. The Pharma Innovation, 1(11, Part A), 29.
9. Borah, R. (2020). Every Minute Matters: Improving the Regulatory Response to Vaccine Development During a Public Health Emergency. Food & Drug LJ, 75, 311.
10. Campbell, E. S., Goens, M. M., Cao, W., Thompson, B., Susta, L., Banadyga, L., & Wootton, S. K. (2023). Recent advancements in AAV-vectored immunoprophylaxis in the nonhuman primate model. Biomedicines, 11(8), 2223.
11. Chakraborty, L., Kaur, A., Rangan, D., & Jacob, J. F. (2021). COVID-19 and Economic Stimulus Packages: Evidence from the Asia-Pacific Region. New Delhi: National Institute of Public Finance and Policy.
12. Choo, K., & Sheikh, A. (2007). Action plans for the long-term management of anaphylaxis: systematic review of effectiveness. Clinical & Experimental Allergy, 37(7), 1090-1094.
13. Chung, E. H. (2014). Vaccine allergies. Clinical and experimental vaccine research, 3(1), 50-57.
14. Delany, I., Rappuoli, R., & De Gregorio, E. (2014). Vaccines for the 21st century. EMBO molecular medicine, 6(6), 708-720.
15. Desai, N., Pande, S., Gholap, A. D., Rana, D., Salave, S., & Vora, L. K. (2024). Regulatory processes involved in clinical trials and intellectual property rights around vaccine development. In Advanced Vaccination Technologies for Infectious and Chronic Diseases (pp. 279-309). Academic Press.
16. Di Pasquale, A., Bonanni, P., Garçon, N., Stanberry, L. R., El-Hodhod, M., & Da Silva, F. T. (2016). Vaccine safety evaluation: practical aspects in assessing benefits and risks. Vaccine, 34(52), 6672-6680.
17. Duffy, S., & Duffy, S. (2023). Development and Stimulation of Adaptive Immune Response. Basic Concepts in Applied Immunology.
18. Duggan, J., Morris, S., Sandefur, J., & Yang, G. (2020). Is the World Bank's COVID-19 Crisis Lending Big Enough, Fast Enough?: New Evidence on Loan Disbursements (No. 554, pp. 1-30). Center for Global Development.
19. Erchick, D. J., Gupta, M., Blunt, M., Bansal, A., Sauer, M., Gerste, A., … & Limaye, R. J. (2022). Understanding determinants of vaccine hesitancy and acceptance in India: A qualitative study of government officials and civil society stakeholders. PloS one, 17(6), e0269606.
20. Etti, M., Fofie, H., Razai, M., Crawshaw, A. F., Hargreaves, S., & Goldsmith, L. P. (2021). Ethnic minority and migrant underrepresentation in Covid-19 research: Causes and solutions. EClinicalMedicine, 36.
21. Fahrni, M. L., Ismail, I. A. N., Refi, D. M., Almeman, A., Yaakob, N. C., Saman, K. M., … & Babar, Z. U. D. (2022). Management of COVID-19 vaccines cold chain logistics: a scoping review. Journal of pharmaceutical policy and practice, 15(1), 16.
22. Fine, P., Eames, K., & Heymann, D. L. (2011). "Herd immunity": a rough guide. Clinical infectious diseases, 52(7), 911-916.
23. Fischer, M., Brinker, A., & Sickmüller, B. (2015). Safety of medicines: detection and reporting adverse reactions. In Local Treatment of Inflammatory Joint Diseases: Benefits and Risks (pp. 1-27). Cham: Springer International Publishing.
24. Fisher, H., Hickman, M., Macleod, J., & Audrey, S. (2018). Adolescent self-consent for vaccinations: protocol for a mixed methods systematic review. BMJ open, 8(5), e021335.
25. Fitzpatrick, T., Yamoah, P., Lacuesta, G., Sadarangani, M., Cook, V., Pourshahnazari, P., … & Special Immunization Clinic Network investigators. (2024). Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study. Vaccine, 42(24), 126078.
26. Gold, M., Goodwin, H., Botham, S., Burgess, M., Nash, M., & Kempe, A. (2000). Re-vaccination of 421 children with a past history of an adverse vaccine reaction in a special immunisation service. Archives of disease in childhood, 83(2), 128-131.
27. Goldenthal, K. L., Midthun, K., & Zoon, K. C. (2011). Control of viral infections and diseases.
28. Hanslik, T., & Boëlle, P. Y. (2007). L'évaluation du rapport risque/bénéfice des stratégies de vaccination. médecine/sciences, 23(4), 391-398.
29. Hauri, A. M., Armstrong, G. L., & HUTiN, Y. J. (2003). Contaminated injections in health care settings. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. Geneva: World Health Organization.

30. Hoffman, M. S., McKeage, J. W., Xu, J., Ruddy, B. P., Nielsen, P. M., & Taberner, A. J. (2023). Minimally invasive capillary blood sampling methods. Expert review of medical devices, 20(1), 5-16.
31. Ikilezi, G., Zlavog, B., Augusto, O. J., Sherr, K., Lim, S. S., & Dieleman, J. L. (2018). Tracking donor funding towards achieving the Global Vaccine Action Plan (GVAP) goals: A landscape analysis (1990–2016). Vaccine, 36(49), 7487-7495.
32. Iwasaki, A., & Pillai, P. S. (2014). Innate immunity to influenza virus infection. Nature Reviews Immunology, 14(5), 315-328.
33. Kartoglu, U., & Ames, H. (2022). Ensuring quality and integrity of vaccines throughout the cold chain: the role of temperature monitoring. Expert Review of Vaccines, 21(6), 799-810.
34. Kavanaugh, M. L., Leong, E., & Haas, M. (2024). Measuring the Relationship Between the 2019 Title X Final Rule and Patients' Sexual and Reproductive Health Care Access and Behavior in Iowa Using a Difference-in-Difference Approach. Sexuality Research and Social Policy, 21(2), 598-615.
35. Kim, H., Park, H., & Lee, S. J. (2017). Effective method for drug injection into subcutaneous tissue. Scientific reports, 7(1), 9613.
36. Ko, M. L., Rao, M., Teare, L., Bridgman, G. C., & Kurian, A. (1995). Outcome of referrals to a district immunisation advisory clinic. Communicable Disease report. CDR Review, 5(10), R146-9.
37. Krantz, M. S., Bruusgaard-Mouritsen, M. A., Koo, G., Phillips, E. J., Stone Jr, C. A., & Garvey, L. H. (2021). Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don't give up on the second dose!. Allergy, 76(9), 2916.
38. Kroger, A. T., Atkinson, W. L., Marcuse, E. K., & Pickering, L. K. (2006). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 55(RR-15), 1-48.
39. Kumar, R., Srivastava, V., Baindara, P., & Ahmad, A. (2022). Thermostable vaccines: An innovative concept in vaccine development. Expert Review of Vaccines, 21(6), 811-824.
40. Lachmann, P. J. (2012). The use of antibodies in the prophylaxis and treatment of infections. Emerging microbes & infections, 1(1), 1-5.
41. Lafeber, A. F., Marzec, A. H. J. O., Labadie, J., van Ommen, R., Strieder, T. G., & Berbers, G. A. M. (2001). MMR vaccine in 14 months old children, intramuscular versus subcutaneous administration.
42. Lazarus, J. V., Karim, S. S. A., Van Selm, L., Doran, J., Batista, C., Amor, Y. B., ... & Yadav, P. (2022). COVID-19 vaccine wastage in the midst of vaccine inequity: causes, types and practical steps. BMJ Global Health, 7(4), e009010.
43. Lofano, G., Mallett, C. P., Bertholet, S., & O'Hagan, D. T. (2020). Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines. NPJ vaccines, 5(1), 88.
44. Makoschey, B. (2015). Modes of vaccine administration at a glance. Berl Münch Tierärztl Wochenschr, 128(11-12), 451-5.
45. Marano, N., Plikaytis, B. D., Martin, S. W., Rose, C., Semenova, V. A., Martin, S. K., ... & Anthrax Vaccine Research Program Working Group. (2008). Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. Jama, 300(13), 1532-1543.
46. Marrero, Y. T., & Suárez, V. M. (2021). Aspectos bioéticos sobre el consentimiento informado en el uso de las vacunas en Pediatría. Revista Habanera de Ciencias Médicas, 20(2), 1-13.
47. Mashunye, T. R. (2019). A systematic review and meta-analysis of fractional dose compared to standard dose inactivated polio vaccination in children.
48. McLure, H. A., & Rubin, A. P. (2005). Review of local anaesthetic agents. Minerva anestesiologica, 71(3), 59-74.
49. McMurtry, C. M., Riddell, R. P., Taddio, A., Racine, N., Asmundson, G. J., Noel, M., ... & Team, H. A. (2015). Far from "just a poke": common painful needle procedures and the development of needle fear. The Clinical journal of pain, 31, S3-S11.
50. Micheletti, F., Moretti, U., Tridente, G., & Zanoni, G. (2011). Consultancy and surveillance of post-immunisation adverse events in the Veneto region of Italy for 1992-2008. Human vaccines, 7(sup1), 234-239.
51. Mohn, K. G. I., Brokstad, K. A., Pathirana, R. D., Bredholt, G., Jul-Larsen, Å., Trieu, M. C., … & Cox, R. J. (2016). Live attenuated influenza vaccine in children induces B-cell responses in tonsils. The Journal of infectious diseases, 214(5), 722-731.
52. Mrozek-Budzyn, D., Kieltyka, A., & Majewska, R. (2010). Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. The Pediatric infectious disease journal, 29(5), 397-400.

53. Nasiru, S. G., Aliyu, G. G., Gasasira, A., Aliyu, M. H., Zubair, M., Mandawari, S. U., … & El-Kamary, S. S. (2012). Breaking community barriers to polio vaccination in Northern Nigeria: the impact of a grass roots mobilization campaign (Majigi). Pathogens and global health, 106(3), 166-171.
54. Nurmatov, U., Worth, A., & Sheikh, A. (2008). Anaphylaxis management plans for the acute and long-term management of anaphylaxis: a systematic review. Journal of Allergy and Clinical Immunology, 122(2), 353-361.
55. Objio, T. (2019). Vaccine storage and handling and vaccine administration.
56. Ojo-Fati, O., Joseph, A. M., Ig-Izevbekhai, J., Thomas, J. L., Everson-Rose, S. A., Pratt, R., … & Okuyemi, K. S. (2017). Practical issues regarding implementing a randomized clinical trial in a homeless population: strategies and lessons learned. Trials, 18, 1-10.
57. Olshansky, S. J., & Hayflick, L. (2017). The role of the WI-38 cell strain in saving lives and reducing morbidity. AIMS public health, 4(2), 127.
58. Orenstein, W. A., & Ahmed, R. (2017). Simply put: Vaccination saves lives. Proceedings of the National Academy of Sciences, 114(16), 4031-4033.
59. Pagliaro, S., Sacchi, S., Pacilli, M. G., Brambilla, M., Lionetti, F., Bettache, K., … & Zubieta, E. (2021). Trust predicts COVID-19 prescribed and discretionary behavioral intentions in 23 countries. PloS one, 16(3), e0248334.
60. Pogarskaya, A. S., & Konfino, K. V. (2022). The implementation of cold chain approach at transportation and storage of immunobiological preparations. Problems of Social Hygiene, Public Health and History of Medicine, 30(4), 666-672.
61. Pulendran, B., & Maddur, M. S. (2015). Innate immune sensing and response to influenza. Influenza Pathogenesis and Control-Volume II, 23-71.
62. Renne, E. (2006). Perspectives on polio and immunization in Northern Nigeria. Social science & medicine, 63(7), 1857-1869.
63. Riedmann, E. M. (2014). Human vaccines & immunotherapeutics: news. Human vaccines & immunotherapeutics, 10(7), 1773-1777.
64. Scarabaggio, P., Carli, R., Cavone, G., Epicoco, N., & Dotoli, M. (2021, August). Modeling, estimation, and optimal control of anti-covid-19 multi-dose vaccine administration. In 2021 IEEE 17th International Conference on Automation Science and Engineering (CASE) (pp. 990-995). IEEE.
65. Senasi, V. (2020). Exploring global and Malaysia's financial stability impact of COVID-19 pandemic.
66. Smith, D. R. (2019). Herd immunity. Veterinary Clinics: Food Animal Practice, 35(3), 593-604.
67. Sommariva, S., Mote, J., Ballester Bon, H., Razafindraibe, H., Ratovozanany, D., Rasoamanana, V., … & Sani, M. (2021). Social listening in Eastern and Southern Africa, a UNICEF risk communication and community engagement strategy to address the COVID-19 infodemic. Health security, 19(1), 57-64.
68. Sutter, R. W., Eisenhawer, M., Molodecky, N. A., Verma, H., & Okayasu, H. (2024). Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance. Pathogens, 13(3), 224.
69. Taddio, A., Chambers, C. T., Halperin, S. A., Ipp, M., Lockett, D., Rieder, M. J., & Shah, V. (2009). Inadequate pain management during routine childhood immunizations: the nerve of it. Clinical therapeutics, 31, S152-S167.
70. Taddio, A., Ipp, M., Thivakaran, S., Jamal, A., Parikh, C., Smart, S., ... & Katz, J. (2012). Survey of the prevalence of immunization non-compliance due to needle fears in children and adults. Vaccine, 30(32), 4807-4812.
71. Taddio, A., McMurtry, C. M., Shah, V., Riddell, R. P., Chambers, C. T., Noel, M., ... & Bleeker, E. V. (2015). Reducing pain during vaccine injections: clinical practice guideline. Cmaj, 187(13), 975-982.
72. Thakur, V. (2021). Framework for PESTEL dimensions of sustainable healthcare waste management: Learnings from COVID-19 outbreak. Journal of cleaner production, 287, 125562.
73. Tomori, O., & Kolawole, M. O. (2021). Ebola virus disease: current vaccine solutions. Current Opinion in Immunology, 71, 27-33.
74. Wallis, J., Shenton, D. P., & Carlisle, R. C. (2019). Novel approaches for the design, delivery and administration of vaccine technologies. Clinical & Experimental Immunology, 196(2), 189-204.
75. Wright, P. F., Hoen, A. G., Ilyushina, N. A., Brown, E. P., Ackerman, M. E., Wieland-Alter, W., ... & Treanor, J. J. (2016, April). Correlates of immunity to influenza as determined by challenge of children with live, attenuated influenza vaccine. In Open Forum Infectious Diseases (Vol. 3, No. 2, p. ofw108). Oxford University Press.